Overexpressed Exogenous IL-4 And IL-10 Paradoxically Regulate Allogenic T-cell and Cardiac Myocytes Apoptosis Through FAS/FASL Pathway
Overview
Affiliations
Background: The authors' previous study has shown that liposome-mediated ex vivo intracoronary interleukin (IL)-4 and IL-10 combined gene therapy suppressed the allo-immune responses and prolonged the cardiac allograft survival by 15 folds. However, the mechanism for promoting long-term allograft survival remains unknown.
Methods: This study tested the hypothesis that this combined cytokine gene targeting may promote alloreactive T-cell apoptosis or prevent apoptosis of cardiac allograft myocytes through Fas/Fas ligand (FasL) pathway. A rabbit functional cervical heterotopic heart transplantation model was used, and plasmid human recombinant IL-4 and IL-10 gene complexed with cationic liposome (GAP/DLRIE) was delivered into cardiac allografts by intracoronary infusion ex vivo.
Results: This liposome-mediated IL-4 and IL-10 combined gene therapy significantly increased apoptotic T cells detected by TUNEL staining. The caspase-8 or caspase-3 expressing T cells were also significantly increased. The Fas+ apoptotic T cells dominated in the population of apoptotic CD4+ T cells, but FasL+ CD4+ T-cell population was less effected in the combined gene therapy group. The effect of combined gene therapy on the infiltrative Fas+ CD8+ T-cell population is much less than that on Fas+ CD4+ cells, and there was almost no effect on the FasL+ CD8+ T-cell population. Furthermore, localized IL-4 and IL-10 combined gene therapy protected cardiac allograft myocytes by down-regulating its FasL expression, but not Fas.
Conclusions: These results suggest that this combined gene targeting strategy which induced localized overexpression of exogenous IL-4 and IL-10 may promote alloreactive T-cell apoptosis and prevent myocytes apoptosis through Fas/FasL cell surface interaction, therefore inducing cardiac allograft tolerance.
Plasmatic Levels of Cytokines and Quality of Life among Elderly Individuals with Dizziness.
Moreira G, de Moraes Marchiori L, Ciquinato D, de Moraes Marchiori G, Okamura L, Branco B Int Arch Otorhinolaryngol. 2025; 29(1):1-7.
PMID: 39845140 PMC: 11753860. DOI: 10.1055/s-0044-1791731.
Liu T, Yang F, Liu J, Zhang M, Sun J, Xiao Y Exp Anim. 2019; 68(4):549-558.
PMID: 31243190 PMC: 6842797. DOI: 10.1538/expanim.19-0037.
Niss O, Sholl A, Bleesing J, Hildeman D J Allergy Clin Immunol. 2014; 135(3):762-70.
PMID: 25174872 PMC: 4344440. DOI: 10.1016/j.jaci.2014.07.020.
Tan C, Gao X, Guo L, Huang H Biomed Res Int. 2014; 2014:856019.
PMID: 24864261 PMC: 4016942. DOI: 10.1155/2014/856019.
Blalock E, Chien H, Dix R Ophthalmol Eye Dis. 2013; 4:79-90.
PMID: 23650460 PMC: 3619657. DOI: 10.4137/OED.S10294.